Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach
Top Cited Papers
Open Access
- 4 January 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Traditional and Complementary Medicine
- Vol. 11 (2), 158-172
- https://doi.org/10.1016/j.jtcme.2020.12.002
Abstract
No abstract availableKeywords
Funding Information
- Chulalongkorn University
This publication has 81 references indexed in Scilit:
- Antioxidant and Antityrosinase Activities of Various Extracts from the Fruiting Bodies of Lentinus lepideusMolecules, 2011
- Medicinal and edible lignicolous fungi as natural sources of antioxidative and antibacterial agentsPhytotherapy Research, 2010
- Inhibition of the Dimerization and Active Site of HIV-1 Protease by Secondary Metabolites from the Vietnamese Mushroom Ganoderma colossumJournal of Natural Products, 2009
- Mechanistic QSAR of aromatic amines: New models for discriminating between homocyclic mutagens and nonmutagens, and validation of models for carcinogensEnvironmental and Molecular Mutagenesis, 2007
- Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main ProteasesPLoS Biology, 2005
- Agrocybin, an antifungal peptide from the edible mushroom Agrocybe cylindraceaPeptides, 2005
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 2001
- Triterpenes from the Spores of Ganoderma lucidum and Their Inhibitory Activity against HIV-1 Protease.CHEMICAL & PHARMACEUTICAL BULLETIN, 1998